In this final installment of the Research You Can Use series, Dr. Gold will share the results and his insights on the findings from a poster presented at Infectious Disease Week (IDWeek 2021) and The Liver Meeting Digital Experience comparing Rapid Treatment and Usual Care in people who inject drugs with the goal of achieving sustained viral response (SVR12).
At the end of this CME/CE activity, participants should be able to compare sustained hepatitis C viral response (SVR12) of rapid treatment with direct-acting antivirals (DAAs) compared to usual care to improve patient outcomes.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, emergency medicine physicians, addiction specialists, harm reduction clinics, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gold has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Susan H. Yarbrough, CHCP (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.